Skip to main content
. 2022 Apr 16;12:6367. doi: 10.1038/s41598-022-10288-8

Table 2.

Summary of re-biopsy result (n = 109).

Diagnosis n (%) T790M n (%) The success rate of re-biopsy (%)

Histology specimens

(n = 59)

Adenocarcinoma 53 (89.8) Positive 32 (54.2) 81.3
Negative 16 (27.1)
No PCR results 5 (8.5)
SCLC transformation 2 (3.4)
Sarcomatoid transformation 1 (1.7)
No malignant cells 3 (5.1)

Cytology specimens

(n = 18)

Adenocarcinoma/malignant cells 14 (77.8) Positive 1 (5.6) 66.7
Negative 11 (61.1)
No PCR results 2 (11.1)
SCLC transformation 1 (5.6)
No malignant cells 3 (16.6)

Plasma liquid biopsy

(n = 32)

Detection of any EGFR mutations 14 (43.8) Positive 8 (25) 43.8
Negative 6 (18.8)
No detection of EGFR mutations 18 (56.2)

Total

(n = 109)

Adenocarcinoma/malignant cells 81 (74.3) Positive 41 (37.6) 67.9
Negative 33 (30.8)
No PCR results 7 (6.4)
Transformation 4 (3.7)
No malignant cells 24 (22)

SCLC, small cell lung cancer; PCR, Polymerase chain reaction; EGFR, epidermal growth factor receptor.